ABCL is trading 6% up at $7.82, extending a multi-session rally. - The surge is driven by a recent major preclinical research collaboration deal with Jazz Pharmaceuticals, involving significant upfront payments and potential milestones. - Technical indicators, including a golden cross in its moving averages, and a positive earnings outlook highlighted by Zacks, also support the upward trend. - Analysts maintain generally upbeat price targets, contributing to improving market sentiment.